Neumora Therapeutics (NMRA) Equity Average (2022 - 2026)

Neumora Therapeutics has reported Equity Average for 5 years, with the latest figure at $87.3 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 66.13% year-over-year to $87.3 million; the trailing twelve-month figure through Mar 2026 stood at $87.3 million (down 66.13% YoY), and the FY2025 full-year result was $195.5 million, down 48.3% from the prior year.
• Equity Average for Q1 2026 stood at $87.3 million, down from $118.0 million in the prior quarter.
• The five-year high for Equity Average was $490.9 million in Q4 2023, with the low at -$495.7 million in Q2 2023.
• Average Equity Average over 5 years is $102.0 million, with a median of $181.6 million recorded in 2025.
• Year-over-year, Equity Average jumped 82882.78% in 2024 and plunged 66.13% in 2026.
• Tracing NMRA's Equity Average over 5 years: stood at -$434.4 million in 2022, then soared by 213.0% to $490.9 million in 2023, then plunged by 38.09% to $303.9 million in 2024, then sank by 61.17% to $118.0 million in 2025, then declined by 26.05% to $87.3 million in 2026.
• The last three Equity Average figures came in at $87.3 million (Q1 2026), $118.0 million (Q4 2025), and $157.5 million (Q3 2025), per Business Quant data.

Peer Comparison